Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chimera Antigen Receptor (CAR)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07500220
What this trial is testing

Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC

Who this might be right for
Advanced Hepatocellular Carcinoma (HCC)Metastatic Liver Cancer
Beijing Biotech 30
Early research (Phase 1)UnknownNCT05349266
What this trial is testing

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B-NHL After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

Who this might be right for
Non-Hodgkin's Lymphoma
Zhejiang University 16
Testing effectiveness (Phase 2)Study completedNCT01747486
What this trial is testing

Dose Optimization Trial of CD19 Redirected Autologous T Cells

Who this might be right for
Adult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL
University of Pennsylvania 42
Testing effectiveness (Phase 2)UnknownNCT05066646
What this trial is testing

A Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)

Who this might be right for
Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd. 132
Early research (Phase 1)Active Not RecruitingNCT06222853
What this trial is testing

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus

Who this might be right for
Systemic Lupus ErythematosusCAR-T Cell Therapy
The Children's Hospital of Zhejiang University School of Medicine 22
Very early researchLooking for participantsNCT07429461
What this trial is testing

Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia

Who this might be right for
B-Cell Acute Lymphoblastic Leukemia
Zhejiang University 16
Early research (Phase 1)Looking for participantsNCT06464679
What this trial is testing

An Exploratory Clinical Study of CD19 CAR NK Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Who this might be right for
Autoimmune Diseases
Changhai Hospital 72
Testing effectiveness (Phase 2)UnknownNCT02685670
What this trial is testing

Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma

Who this might be right for
Hematopoietic/Lymphoid CancerAdult Acute Lymphoblastic Leukemia in RemissionB-cell Adult Acute Lymphoblastic Leukemia+19 more
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine 20
Early research (Phase 1)Study completedNCT03049449
What this trial is testing

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

Who this might be right for
Lymphoma, Large-Cell, AnaplasticEnteropathy-Associated T-Cell LymphomaLymphoma, Large B-Cell, Diffuse+2 more
National Cancer Institute (NCI) 26
Early research (Phase 1)Not Yet RecruitingNCT07765966
What this trial is testing

Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias

Who this might be right for
Immune Thrombocytopenia (ITP)
RiboX Therapeutics Ltd. 27
Early research (Phase 1)Looking for participantsNCT06768151
What this trial is testing

A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer

Who this might be right for
Advanced Lung Cancer
Chongqing Precision Biotech Co., Ltd 48
Early research (Phase 1)Active Not RecruitingNCT01840566
What this trial is testing

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center 17
Early research (Phase 1)Ended earlyNCT02706392
What this trial is testing

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

Who this might be right for
Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmMetastatic Lung Non-Small Cell Carcinoma+10 more
Fred Hutchinson Cancer Center 21
Early research (Phase 1)Study completedNCT02631044
What this trial is testing

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

Who this might be right for
Non-Hodgkin LymphomaDiffuse Large B Cell LymphomaFollicular Lymphoma+2 more
Juno Therapeutics, a Subsidiary of Celgene 387
Very early researchUnknownNCT04626752
What this trial is testing

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd. 50
Testing effectiveness (Phase 2)WithdrawnNCT06005649
What this trial is testing

Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Non-hodgkin Lymphoma
Juventas Cell Therapy Ltd.
Testing effectiveness (Phase 2)Active Not RecruitingNCT03971799
What this trial is testing

Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myelogenous Leukemia
Center for International Blood and Marrow Transplant Research 52
Early research (Phase 1)Ended earlyNCT03593109
What this trial is testing

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Second Affiliated Hospital of Xi'an Jiaotong University 1
Testing effectiveness (Phase 2)UnknownNCT03130712
What this trial is testing

GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)

Who this might be right for
Carcinoma, Hepatocellular
Shanghai GeneChem Co., Ltd. 10
Testing effectiveness (Phase 2)Looking for participantsNCT07564401
What this trial is testing

Evaluate DJI136, a DLL3-targeted CAR-T Therapy

Who this might be right for
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Novartis Pharmaceuticals 80
Next Page